4-1BB Ligand (4 1BB Ligand)

A membrane bound member of the TNF superfamily that is expressed on activated B-LYMPHOCYTES; MACROPHAGES; and DENDRITIC CELLS. The ligand is specific for the 4-1BB RECEPTOR and may play a role in inducing the proliferation of activated peripheral blood T-LYMPHOCYTES.

Also Known As:

Networked: 96 relevant articles (6 outcomes, 11 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Schwarz, Herbert: 9 articles (01/2020 - 03/2005)
2.	Kwon, Byoung S: 4 articles (11/2017 - 07/2003)
3.	Ye, Jianxin: 3 articles (05/2017 - 02/2013)
4.	Yagita, Hideo: 3 articles (10/2013 - 11/2004)
5.	Watts, Tania H: 3 articles (08/2011 - 04/2002)
6.	Kiener, P A: 3 articles (08/2006 - 09/2000)
7.	Salih, H R: 3 articles (08/2006 - 09/2000)
8.	Wong, Hiu Yi: 2 articles (01/2020 - 01/2020)
9.	Hansson, Göran K: 2 articles (11/2017 - 03/2008)
10.	Hedin, Ulf: 2 articles (11/2017 - 03/2008)

Related Diseases

1.	Human Influenza (Influenza) 01/15/2009 - "Endogenous 4-1BB ligand plays a critical role in protection from influenza-induced disease." 04/15/2002 - "Temporal segregation of 4-1BB versus CD28-mediated costimulation: 4-1BB ligand influences T cell numbers late in the primary response and regulates the size of the T cell memory response following influenza infection." 01/15/2009 - "During mild respiratory influenza infection in which virus is rapidly cleared, the inducible costimulatory receptor 4-1BB is only transiently induced on lung T cells and 4-1BB ligand (4-1BBL) is completely dispensable for the initial CD8 T cell response and mouse survival. " 08/26/2011 - "Incorporation of 4-1BB ligand into an adenovirus vaccine vector increases the number of functional antigen-specific CD8 T cells and enhances the duration of protection against influenza-induced respiratory disease."
2.	Neoplasms (Cancer) 11/01/2017 - "Anti-CD137 Suppresses Tumor Growth by Blocking Reverse Signaling by CD137 Ligand." 01/01/2014 - "By fusion of a costimulatory domain (for example, the extracellular CD137 ligand domain) to the TM, the targeting complex can even provide a costimulatory signal to the redirected T cells at their side of interaction with the tumor cell. " 05/26/2010 - "Since CD137 ligand cross-linking enhances proliferation and survival of healthy B cells we hypothesized that it would also act as a growth stimulus for B cell cancers. " 06/01/2007 - "[Construction and expression of eukaryotic expression vector of human 4-1BB ligand gene in tumor cells and its antitumor activity in vitro]." 03/01/2007 - "B7-1 and 4-1BB ligand expression on a myeloma cell line makes it possible to expand autologous tumor-specific cytotoxic T cells in vitro."
3.	Carcinoma (Carcinomatosis) 05/01/2006 - "The CD137 ligand (CD137L) is expressed by antigen-presenting cells including macrophages, but also on various carcinoma cells. " 09/01/2000 - "Constitutive expression of functional 4-1BB (CD137) ligand on carcinoma cells." 10/01/2008 - "4-1BB (CD137) ligand enhanced anti-tumor immune response against mouse forestomach carcinoma in vivo." 10/01/2014 - "Artificial antigen presenting cells (aAPCs) were produced by transduction of CD80, 4-1BB ligand or green fluorescent protein genes into A549 carcinoma cells using recombinant adenoviral vectors. " 05/01/2012 - "Stimulation of non-adherent PBMC with OVCAR-3 cells expressing 4-1BB ligand (4-1BBL) or IL-12 resulted in preferential expansion of the NK cell population, while the combination 4-1BBL + IL-12 was superior for the activation and proliferation of functional NK cells from healthy donors and patients with renal cell or ovarian carcinoma, supporting long-term (21 day) NK cell proliferation. "
4.	Melanoma (Melanoma, Malignant) 01/01/2020 - "Depletion of CD8+ T cells or blockade of the CD137 ligand-receptor interaction reduced time to regrowth of melanomas in the context of treatment with CDK4/6i plus MEKi treatment in vivo Together, our data outline an antitumor immune-based mechanism and show the efficacy of targeting both the MEK pathway and CDK4/6." 10/01/2016 - "The results from this study show that the costimulatory 4-1BB ligand fortifies an antigen-rich melanoma cell line with enhanced antigen-specific stimulation of CD8 T cells. " 03/26/2021 - "Human melanoma cells were infected by OVs armed with costimulatory molecules CD40 ligand (CD40L) and 4-1BB ligand (4-1BBL). " 10/01/2016 - "To enhance their specific antitumor activity, we aimed to improve a melanoma cell-based vaccine by transfecting it with 4-1BB ligand, a costimulatory and immune modulatory molecule. "
5.	Neoplasm Metastasis (Metastasis) 06/07/2000 - "Immunomodulatory gene therapy with interleukin 12 and 4-1BB ligand: long- term remission of liver metastases in a mouse model." 06/01/2002 - "In this study, we compared the effect of a systemically delivered agonistic anti-4-1BB monoclonal antibody (anti-4-1BB mAb) with intra-tumoral adenoviral-mediated gene transfer of the 4-1BB ligand (ADV/4-1BBL) to liver metastases in a syngeneic animal model of breast cancer. " 06/01/2002 - "T cell activation with systemic agonistic antibody versus local 4-1BB ligand gene delivery combined with interleukin-12 eradicate liver metastases of breast cancer."

Related Drugs and Biologics

1.	Antigens
2.	Proteins (Proteins, Gene)
3.	Survivin
4.	Interleukin-12 (IL 12)
5.	Adenovirus Vaccines
6.	Member 9 Tumor Necrosis Factor Receptor Superfamily
7.	Mitogen-Activated Protein Kinase Kinases (MEKs)
8.	Vaccines
9.	Ligands
10.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)

Related Therapies and Procedures

1.	Therapeutics
2.	Immunotherapy
3.	Ligation